Summary of the Conference Call on China's CRO Industry Industry Overview - The conference call focuses on the **China CRO (Contract Research Organization) industry** and its global competitiveness from short-term, medium-term, and long-term perspectives [1][2]. Key Insights and Arguments - **Strong Performance in 2024-2025**: The Chinese CRO industry is expected to perform strongly in 2024-2025, driven by policy support, AI technology applications, and robust performance from companies like WuXi AppTec, which has seen significant stock price increases [1]. - **Geopolitical Risks**: Despite challenges from geopolitical factors such as India's PLI scheme and the US Biodefense Act, the risks are considered manageable due to China's comprehensive advantages in chemical capabilities, compliance capacity, and intellectual property protection [1][5]. - **Supply and Demand Dynamics**: The small molecule supply peak has passed, while the large molecule sector remains in a high investment phase. The global pharmaceutical pipeline and R&D investments continue to grow, with a strong demand side indicated by the increasing number of clinical trial registrations in China [1][6]. - **Investment Trends**: Overall R&D investment is on the rise, although growth rates may slow. In the large molecule CDMO sector, WuXi Biologics' revenue growth is slower than that of Samsung Biologics, with guidance for 2025 set at 14%-16% for WuXi and 25%-30% for Samsung [7]. - **Order Growth**: In the large molecule CDMO sector, WuXi Biologics has $4.2 billion in unfulfilled orders, a 15.3% year-on-year increase, while Samsung has $18.7 billion, up 43.8%. WuXi AppTec's new contract amounts have also shown significant growth [8]. Additional Important Content - **Emerging Business Layouts**: Several CRO companies are venturing into emerging fields such as peptides and oligonucleotides. Investment recommendations suggest favoring companies with strong valuations and competitive positions in the small molecule sector, with WuXi AppTec highlighted as a key player [12][13]. - **Capital Expenditure**: Capital expenditures remain high in the large molecule sector, with companies like Samsung and WuXi maintaining significant investments. WuXi AppTec plans to invest at least 7-8 billion yuan in 2025, reflecting confidence in future growth [11]. - **Clinical CRO Performance**: Clinical CROs are currently experiencing performance fluctuations, but order growth indicates potential recovery. Companies like Tigermed and PPD have reported double-digit order growth, suggesting a positive outlook for future performance [9][10]. This summary encapsulates the key points discussed in the conference call regarding the current state and future outlook of the Chinese CRO industry, highlighting both opportunities and challenges.

Group 1 - The A-share market saw a widespread decline in pharmaceutical stocks, with notable drops including Sunflower, Hanyu Pharmaceutical, and Kailaiying, each falling over 3% [1] - The U.S. President announced a new round of high tariffs on various imported products, including a 100% tariff on all brands and patented pharmaceutical products starting October 1 [1] Group 2 - Specific stock performance data shows that ST Complex dropped by 4.98%, with a total market value of 3.886 billion, and a year-to-date decline of 12.94% [2] - Sunflower's market value is 11.1 billion, with a year-to-date increase of 166.98%, despite a recent drop of 3.89% [2] - Hanyu Pharmaceutical's market value stands at 19.8 billion, with a year-to-date increase of 73.62%, and a recent decline of 3.20% [2] - Kailaiying's market value is 39.1 billion, with a year-to-date increase of 44.26%, and a recent drop of 3.01% [2] - Other companies such as Maiwei Bio, Zhaoyan New Drug, and Kanglong Chemical also experienced declines of over 2% [1][2]

来源：新浪港股 香港联交所最新资料显示，9月23日，Schroders PLC增持凯莱英（06821）11.14万股，每股均价94.4487 港元，总金额约为1052.16万港元。增持后最新持股数目为580.43万股，最新持股比例为21.07%。 ...

增持后，Schroders PLC最新持股数目为580.43万股，持股比例由20.66%上升至21.07%。责任编辑：栎树 格隆汇9月26日丨根据联交所最新权益披露资料显示，2025年9月23日，凯莱英(06821.HK)获Schroders PLC在场内以每股均价94.4487港元增持11.14万股，涉资约1052.2万港元。 ...

| 股份代號: | 06821 | | --- | --- | | 上市法國名稱: | 凱萊英醫藥集團(天津)股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 26/08/2025 - 26/09/2025 | 格隆汇9月26日丨根据联交所最新权益披露资料显示，2025年9月23日，凯莱英(06821.HK)获Schroders PLC在场内以每股均价94.4487港元增持11.14万股，涉 资约1052.2万港元。 增持后，Schroders PLC最新持股数目为580.43万股，持股比例由20.66%上升至21.07%。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 有投票權股期(日/月/ 份權益 | | | | | | | | 10 份百分比 年) | | | | | | | | ( % ) | | CS2025 ...

香港联交所最新资料显示，9月23日，Schroders PLC增持凯莱英（002821）(06821)11.14万股，每股均价 94.4487港元，总金额约为1052.16万港元。增持后最新持股数目为580.43万股，最新持股比例为 21.07%。 ...

Investment Rating - The industry rating is "Overweight" (maintained) [5] Core Insights - The collaboration between Maiwei Biotech, Yingsi Intelligent, and Haoyuan Pharmaceutical aims to create a novel ADC (Antibody-Drug Conjugate) compound library covering hundreds of targets, accelerating the industrialization of next-generation ADC drugs, which are considered a promising direction in cancer treatment [5][6] - This partnership highlights a shift in China's pharmaceutical innovation model from a singular "independent R&D" approach to a more collaborative ecosystem that integrates strategic alliances and shared research platforms, which helps mitigate early-stage R&D risks and optimizes resource allocation [7] Summary by Sections Recent Industry Performance - Over the past 12 months, the industry has shown a relative return of 5.97% compared to the CSI 300 index, with an absolute return of 42.2% [3] Investment Highlights - The collaboration combines strengths from various fields: Maiwei Biotech's experience in antibody drug development, Yingsi Intelligent's AI technology for target discovery and molecular design, and Haoyuan Pharmaceutical's expertise in high-end chemical raw materials [7] - The ADC drugs are positioned in a rapidly growing global market, with the collaboration aiming to systematically lay out core resources for future ADC drug development [7] - The report suggests monitoring the capital market movements of the collaborating companies, as their progress may act as a catalyst for stock price changes [7] Recommendations - The report recommends focusing on the entire ADC industry chain, including upstream CXO companies with advanced toxin-Linker technology, midstream innovative pharmaceutical companies with leading ADC platforms, and downstream large pharmaceutical companies with strong commercialization capabilities in oncology [7] - Specific companies to watch include Maiwei Biotech, Haoyuan Pharmaceutical, Rongchang Biotech, WuXi AppTec, Kailaiying, Nanfeng Technology, and Dongfulong [7]

Group 1 - The innovative drug sector in A-shares and H-shares continues to rise, with notable stocks such as Aosaikang and Junshi Biosciences showing significant gains [1] - Aosaikang's subsidiary has completed the first patient dosing in a Phase III clinical trial for a new drug targeting advanced non-small cell lung cancer [1] - Heng Rui Medicine has licensed its innovative drug to Glenmark Specialty for an upfront payment of $18 million and potential milestone payments totaling up to $1.093 billion [1] Group 2 - The Hong Kong innovative drug ETF (513120) has seen a rise of over 1%, with leading stocks like Junshi Biosciences and Rongchang Bio leading the gains [2] - The innovative drug ETF (515120) has also experienced a nearly 2% increase, with significant inflows totaling 699 million yuan over the past 20 trading days [2] - Tianfeng Securities highlights that the Chinese innovative drug industry is forming a pyramid structure led by top enterprises, indicating strong sustainability in the sector [2] Group 3 - The Hong Kong innovative drug ETF (513120) allows T+0 trading, enhancing liquidity and capital efficiency for investors [3] - The innovative drug ETF (515120) closely tracks the innovative drug industry index in A-shares, covering various aspects of drug development and sales [3]

Group 1 - The CRO index experienced an intraday increase of 2.01%, indicating strong market performance in the sector [1] - Jiuzhou Pharmaceutical reached its daily limit up, showcasing significant investor interest [1] - Zhaoyan New Drug and Aopu Mai saw respective increases of 3.49% and 3.40%, reflecting positive momentum among key players [1] - WuXi AppTec and Kelai Ying both recorded gains exceeding 2.5%, further highlighting the active performance of the CRO sector [1]

智通财经APP获悉，香港联交所最新数据显示，9月22日，Norges Bank减持凯莱英(06821)5.62万股，每 股作价99.4441港元，总金额约为558.88万港元。减持后最新持股数目为327.08万股，最新持股比例为 11.87%。 ...